<DOC>
	<DOCNO>NCT02584634</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy avelumab combine either crizotinib PF-06463922 .</brief_summary>
	<brief_title>Study Evaluate Safety , Efficacy , Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC . ( Javelin Lung 101 )</brief_title>
	<detailed_description>This Phase 1b/2 , open label , multi center , multiple dose , safety , pharmacokinetic pharmacodynamic study Group A Group B cohorts adult patient locally advance metastatic NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Inclusion Criteria Diagnosis advance metastatic NSCLC . Group A must ALK negative NSCLC Group B must ALK positive NSCLC Group A least one prior regimen therapy Group B number prior regimens . Mandatory tumor tissue available At least one measurable lesion ECOG Performance status 0 1 Adequate bone marrow , renal , liver pancreatic function Negative pregnancy test female childbearing potential No prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody . No Severe Chronic medical condition include gastrointestinal abnormality significant cardiac history No active infection require systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>ALK</keyword>
	<keyword>avelumab</keyword>
	<keyword>crizotinib</keyword>
	<keyword>PF-06463922</keyword>
</DOC>